5/2
04:00 pm
cytk
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/29
04:12 pm
cytk
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress [Yahoo! Finance]
Low
Report
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress [Yahoo! Finance]
4/29
04:00 pm
cytk
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Low
Report
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
4/24
04:00 pm
cytk
Cytokinetics to Announce First Quarter Results on May 8, 2024
Medium
Report
Cytokinetics to Announce First Quarter Results on May 8, 2024
4/10
07:39 am
cytk
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress [Yahoo! Finance]
Low
Report
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress [Yahoo! Finance]
4/10
07:30 am
cytk
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Low
Report
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
4/9
08:09 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $108.00 price target on the stock.
Low
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $108.00 price target on the stock.
4/8
11:23 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $86.00 price target on the stock.
Low
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $86.00 price target on the stock.
4/5
07:44 am
cytk
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73?? Annual Scientific Session [Yahoo! Finance]
Medium
Report
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73?? Annual Scientific Session [Yahoo! Finance]
4/5
07:30 am
cytk
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73?? Annual Scientific Session
Medium
Report
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73?? Annual Scientific Session
4/5
07:30 am
cytk
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73?? Annual Scientific Session
Medium
Report
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73?? Annual Scientific Session
4/3
12:14 pm
cytk
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS [Yahoo! Finance]
Low
Report
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS [Yahoo! Finance]
4/2
04:00 pm
cytk
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/1
04:09 pm
cytk
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Low
Report
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
4/1
04:00 pm
cytk
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
4/1
06:12 am
cytk
Cytokinetics, Incorporated: Buyout Speculation Persists [Seeking Alpha]
Low
Report
Cytokinetics, Incorporated: Buyout Speculation Persists [Seeking Alpha]
3/26
02:05 pm
cytk
Cytokinetics gains amid renewed takeover speculation [Seeking Alpha]
Low
Report
Cytokinetics gains amid renewed takeover speculation [Seeking Alpha]
3/25
08:24 am
cytk
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session [Yahoo! Finance]
Medium
Report
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session [Yahoo! Finance]
3/25
08:15 am
cytk
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
Medium
Report
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
3/20
08:35 am
cytk
2 Incredible Growth Stocks to Buy Right Now [Yahoo! Finance]
Low
Report
2 Incredible Growth Stocks to Buy Right Now [Yahoo! Finance]
3/16
04:07 am
cytk
Cytokinetics: CEO Talks Down Buyout Prospects [Seeking Alpha]
Low
Report
Cytokinetics: CEO Talks Down Buyout Prospects [Seeking Alpha]
3/11
03:55 pm
cytk
Cytokinetics drifts lower as CEO touts standalone strategy [Seeking Alpha]
Low
Report
Cytokinetics drifts lower as CEO touts standalone strategy [Seeking Alpha]
3/6
08:40 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Mizuho from $103.00 to $99.00. They now have a "buy" rating on the stock.
Low
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Mizuho from $103.00 to $99.00. They now have a "buy" rating on the stock.
3/4
04:22 pm
cytk
Cytokinetics to Participate in March Investor Conferences [Yahoo! Finance]
Low
Report
Cytokinetics to Participate in March Investor Conferences [Yahoo! Finance]
3/4
04:00 pm
cytk
Cytokinetics to Participate in March Investor Conferences
Low
Report
Cytokinetics to Participate in March Investor Conferences